Inhibition of Pyrimidine Biosynthesis Pathway Suppresses Viral Growth through Innate Immunity

PLoS Pathogens

Volumn 9, Issue 10, 2013, Pages

  Lucas Hourani, Marianne ^a,b   Dauzonne, Daniel ^c,d   Jorda, Pierre ^c,d   Cousin, Gaëlle ^c,d   Lupan, Alexandru ^a,d,g   Helynck, Olivier ^a,d   Caignard, Grégory ^a,b,h   Janvier, Geneviève ^a,b   André Leroux, Gwénaëlle ^a,d,i   Khiar, Samira ^a,b   Escriou, Nicolas ^a,b   Desprès, Philippe ^a   Jacob, Yves ^b,e,f   Munier Lehmann, Hélène ^a,d   Tangy, Frédéric ^a,b   Vidalain, Pierre Olivier ^a,b  

^a INSTITUT PASTEUR   (France)

^b Institut Pasteur   (France)

^c INSTITUT CURIE   (France)

^d CNRS   (France)

^e Sorbonne Paris Cité   (France)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g BABE BOLYAI UNIVERSITY   (Romania)

^h MCGILL UNIVERSITY   (Canada)

ⁱ CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BREQUINAR; CYTIDINE; DD 264; GUANOSINE; INTERFERON REGULATORY FACTOR 1; MYCOPHENOLIC ACID; OROTIC ACID; PYRIMIDINE ANTAGONIST; UNCLASSIFIED DRUG; URIDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; METABOLIC STRESS; NUCLEAR EXPORT SIGNAL; PYRIMIDINE SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS; STRUCTURE ACTIVITY RELATION; VIROGENESIS;

ALPHAVIRUS INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CHIKUNGUNYA VIRUS; HELA CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-1; PYRIMIDINES; VERO CELLS;

EID: 84887297004     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003678     Document Type: Article

References (73)

1. Leyssen P, De Clercq E, Neyts J, (2008) Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res 78: 9-25.
2. Wang BX, Fish EN, (2012) The yin and yang of viruses and interferons. Trends Immunol 33: 190-197.
3. Tan SL, Ganji G, Paeper B, Proll S, Katze MG, (2007) Systems biology and the host response to viral infection. Nat Biotechnol 25: 1383-1389.
4. Krumm SA, Ndungu JM, Yoon JJ, Dochow M, Sun A, et al. (2011) Potent host-directed small-molecule inhibitors of myxovirus RNA-dependent RNA-polymerases. PLoS One 6: e20069.
5. Mata MA, Satterly N, Versteeg GA, Frantz D, Wei S, et al. (2011) Chemical inhibition of RNA viruses reveals REDD1 as a host defense factor. Nat Chem Biol 7: 712-719.
6. Prussia A, Thepchatri P, Snyder JP, Plemper RK, (2011) Systematic Approaches towards the Development of Host-Directed Antiviral Therapeutics. Int J Mol Sci 12: 4027-4052.
7. Cheng G, Wang LC, Fridlender ZG, Cheng GS, Chen B, et al. (2011) Pharmacologic activation of the innate immune system to prevent respiratory viral infections. Am J Respir Cell Mol Biol 45: 480-488.
8. Shirey KA, Nhu QM, Yim KC, Roberts ZJ, Teijaro JR, et al. (2011) The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-beta-mediated antiviral activity in vitro and in vivo. J Leukoc Biol 89: 351-357.
9. Guo F, Mead J, Aliya N, Wang L, Cuconati A, et al. (2012) RO 90-7501 Enhances TLR3 and RLR Agonist Induced Antiviral Response. PLoS One 7: e42583.
10. Es-Saad S, Tremblay N, Baril M, Lamarre D, (2012) Regulators of innate immunity as novel targets for panviral therapeutics. Curr Opin Virol 2: 622-628.
11. Stetson DB, Medzhitov R, (2006) Type I interferons in host defense. Immunity 25: 373-381.
12. Baum A, Garcia-Sastre A, (2010) Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 38: 1283-1299.
13. Arpaia N, Barton GM, (2011) Toll-like receptors: key players in antiviral immunity. Curr Opin Virol 1: 447-454.
14. Loo YM, Gale M Jr, (2011) Immune signaling by RIG-I-like receptors. Immunity 34: 680-692.
15. van Boxel-Dezaire AHH, Rani MRS, Stark GR, (2006) Complex modulation of cell type-specific signaling in response to type I Interferons. Immunity 25: 361-372.
16. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
17. MacMicking JD, (2012) Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat Rev Immunol 12: 367-382.
18. Connolly DJ, O'Neill LA, (2012) New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol.
19. Konishi H, Okamoto K, Ohmori Y, Yoshino H, Ohmori H, et al. (2012) An orally available, small-molecule interferon inhibits viral replication. Sci Rep 2: 259.
20. Lin CW, Wu CF, Hsiao NW, Chang CY, Li SW, et al. (2008) Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int J Antimicrob Agents 32: 355-359.
21. Bedard KM, Wang ML, Proll SC, Loo YM, Katze MG, et al. (2012) Isoflavone Agonists of IRF-3 Dependent Signaling Have Antiviral Activity against RNA Viruses. J Virol 86: 7334-7344.
22. Tai ZF, Zhang GL, Wang F, (2012) Identification of small molecule activators of the janus kinase/signal transducer and activator of transcription pathway using a cell-based screen. Biol Pharm Bull 35: 65-71.
23. Patel DA, Patel AC, Nolan WC, Zhang Y, Holtzman MJ, (2012) High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery. PLoS One 7: e36594.
24. Martinez-Gil L, Ayllon J, Ortigoza MB, Garcia-Sastre A, Shaw ML, et al. (2012) Identification of small molecules with type I interferon inducing properties by high-throughput screening. PLoS One 7: e49049.
25. Ortigoza MB, Dibben O, Maamary J, Martinez-Gil L, Leyva-Grado VH, et al. (2012) A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon. PLoS Pathog 8: e1002668.
26. Kummerer BM, Grywna K, Glasker S, Wieseler J, Drosten C, (2012) Construction of an infectious Chikungunya virus cDNA clone and stable insertion of mCherry reporter genes at two different sites. J Gen Virol 93: 1991-1995.
27. Bourai M, Lucas-Hourani M, Gad HH, Drosten C, Jacob Y, et al. (2012) Mapping of Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component. J Virol 86: 3121-3134.
28. Henrik Gad H, Paulous S, Belarbi E, Diancourt L, Drosten C, et al. (2012) The E2-E166K substitution restores Chikungunya virus growth in OAS3 expressing cells by acting on viral entry. Virology.
29. Dauzonne D, Demerseman P, (1990) Potassium Fluoride-Promoted Reaction of (2-Chloro-2-nitroethenyl)benzenes with 1,3-Dicarbonyl Compounds- A General Synthesis of 6,6-Dimethyl-2-nitro-3-phenyl-3,5,6,7-tetrahydro-4(2H)benzofuranones and some Analogs. J Heterocyclic Chem 27: 1581-1584.
30. Dauzonne D, Josien H, Demerseman P, (1990) (2-Chloro-2-nitroethenyl)benzenes as Synthons- a General-Method for the Preparation of 2,3-Dihydro-2-nitro-3-phenyl-4H-furo[3,2-c][1]benzopyran-4-ones and 3-Phenyl-4H-furo[3,2-c][1]benzopyran-4-ones. Tetrahedron 46: 7359-7371.
31. Dauzonne D, Adam-Launay A, (1992) A Convenient Procedure for the Preparation of 5,6-Dihydro-6-nitro-5-phenylfuro[2,3-d]pyrimidin-4(3H)-ones and 5-Phenylfuro[2,3-d]pyrimidin-4(3H)-ones. Tetrahedron 48: 3069-3080.
32. Raimondi W, Dauzonne D, Constantieux T, Bonne D, Rodriguez J, (2012) Expeditious, Metal-Free, Domino, Regioselective Synthesis of Highly Substituted 2-Carbonyl- and 2-Phosphorylfurans by Formal [3+2] Cycloaddition. Eur J Org Chem pp. 6119-6123.
33. Bonavia A, Franti M, Pusateri Keaney E, Kuhen K, Seepersaud M, et al. (2011) Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci U S A 108: 6739-6744.
34. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, et al. (2011) Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 85: 6548-6556.
35. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML, (2011) Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 108: 5777-5782.
36. Smee DF, Hurst BL, Day CW, (2012) D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 22: 263-272.
37. Khutornenko AA, Roudko VV, Chernyak BV, Vartapetian AB, Chumakov PM, et al. (2010) Pyrimidine biosynthesis links mitochondrial respiration to the p53 pathway. Proc Natl Acad Sci U S A 107: 12828-12833.
38. Planterose DN, (1969) Antiviral and cytotoxic effects of mycophenolic acid. J Gen Virol 4: 629-630.
39. Padalko E, Verbeken E, Matthys P, Aerts JL, De Clercq E, et al. (2003) Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol 3: 25.
40. Khan M, Dhanwani R, Patro IK, Rao PV, Parida MM, (2011) Cellular IMPDH enzyme activity is a potential target for the inhibition of Chikungunya virus replication and virus induced apoptosis in cultured mammalian cells. Antiviral Res 89: 1-8.
41. Liu S, Neidhardt EA, Grossman TH, Ocain T, Clardy J, (2000) Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure 8: 25-33.
42. Dixit E, Boulant S, Zhang Y, Lee AS, Odendall C, et al. (2010) Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141: 668-681.
43. Meng Z, Zhang X, Wu J, Pei R, Xu Y, et al. (2013) RNAi Induces Innate Immunity through Multiple Cellular Signaling Pathways. PLoS One 8: e64708.
44. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, et al. (1993) Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75: 83-97.
45. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, et al. (2000) Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13: 539-548.
46. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, et al. (1997) Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275: 540-543.
47. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, et al. (2005) Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434: 243-249.
48. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, et al. (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
49. Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, et al. (1996) Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87: 307-317.
50. Kimura T, Kadokawa Y, Harada H, Matsumoto M, Sato M, et al. (1996) Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. Genes Cells 1: 115-124.
51. Masumi A, Wang IM, Lefebvre B, Yang XJ, Nakatani Y, et al. (1999) The histone acetylase PCAF is a phorbol-ester-inducible coactivator of the IRF family that confers enhanced interferon responsiveness. Mol Cell Biol 19: 1810-1820.
52. Dornan D, Eckert M, Wallace M, Shimizu H, Ramsay E, et al. (2004) Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol Cell Biol 24: 10083-10098.
53. Narayan V, Pion E, Landre V, Muller P, Ball KL, (2011) Docking-dependent ubiquitination of the interferon regulatory factor-1 tumor suppressor protein by the ubiquitin ligase CHIP. J Biol Chem 286: 607-619.
54. Narayan V, Halada P, Hernychova L, Chong YP, Zakova J, et al. (2011) A multiprotein binding interface in an intrinsically disordered region of the tumor suppressor protein interferon regulatory factor-1. J Biol Chem 286: 14291-14303.
55. Sgarbanti M, Remoli AL, Marsili G, Ridolfi B, Borsetti A, et al. (2008) IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J Virol 82: 3632-3641.
56. Park J, Kim K, Lee EJ, Seo YJ, Lim SN, et al. (2007) Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc Natl Acad Sci U S A 104: 17028-17033.
57. Masumi A, Ozato K, (2001) Coactivator p300 acetylates the interferon regulatory factor-2 in U937 cells following phorbol ester treatment. J Biol Chem 276: 20973-20980.
58. Pan Q, de Ruiter PE, Metselaar HJ, Kwekkeboom J, de Jonge J, et al. (2012) Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology 55: 1673-1683.
59. Zhang L, Das P, Schmolke M, Manicassamy B, Wang Y, et al. (2012) Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export. J Cell Biol 196: 315-326.
60. Paladino P, Mossman KL, (2009) Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J Interferon Cytokine Res 29: 599-607.
61. Evers DL, Wang X, Huong SM, Andreoni KA, Huang ES, (2005) Inhibition of human cytomegalovirus signaling and replication by the immunosuppressant FK778. Antiviral Res 65: 1-12.
62. Vastag L, Koyuncu E, Grady SL, Shenk TE, Rabinowitz JD, (2011) Divergent effects of human cytomegalovirus and herpes simplex virus-1 on cellular metabolism. PLoS Pathog 7: e1002124.
63. Knight DA, Hejmanowski AQ, Dierksheide JE, Williams JW, Chong AS, et al. (2001) Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide. Transplantation 71: 170-174.
64. Vyas VK, Ghate M, (2011) Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev Med Chem 11: 1039-1055.
65. Munier-Lehmann H, Vidalain PO, Tangy F, Janin YL, (2013) On Dihydroorotate Dehydrogenases and Their Inhibitors and Uses. J Med Chem.
66. Davis IC, Lazarowski ER, Chen FP, Hickman-Davis JM, Sullender WM, et al. (2007) Post-infection A77-1726 blocks pathophysiologic sequelae of respiratory syncytial virus infection. Am J Respir Cell Mol Biol 37: 379-386.
67. Dunn MC, Knight DA, Waldman WJ, (2011) Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antivir Ther 16: 309-317.
68. Hibert MF, (2009) French/European academic compound library initiative. Drug Discov Today 14: 723-725.
69. Komarova AV, Combredet C, Meyniel-Schicklin L, Chapelle M, Caignard G, et al. (2011) Proteomic analysis of virus-host interactions in an infectious context using recombinant viruses. Mol Cell Proteomics 10: M110 007443.
70. Combredet C, Labrousse V, Mollet L, Lorin C, Delebecque F, et al. (2003) A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. J Virol 77: 11546-11554.
71. Brehin AC, Rubrecht L, Navarro-Sanchez ME, Marechal V, Frenkiel MP, et al. (2008) Production and characterization of mouse monoclonal antibodies reactive to Chikungunya envelope E2 glycoprotein. Virology 371: 185-195.
72. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
73. Contreras-Sanz A, Scott-Ward TS, Gill HS, Jacoby JC, Birch RE, et al. (2012) Simultaneous quantification of 12 different nucleotides and nucleosides released from renal epithelium and in human urine samples using ion-pair reversed-phase HPLC. Purinergic Signal 8: 741-751.